Inhibition of respiratory viruses by nasally administered siRNA
Top Cited Papers
- 26 December 2004
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 11 (1) , 50-55
- https://doi.org/10.1038/nm1164
Abstract
Respiratory syncytial virus (RSV) and parainfluenza virus (PIV) are two respiratory pathogens of paramount medical significance that exert high mortality. At present, there is no reliable vaccine or antiviral drug against either virus. Using an RNA interference (RNAi) approach, we show that individual as well as joint infection by RSV and PIV can be specifically prevented and inhibited by short interfering RNAs (siRNAs), instilled intranasally in the mouse, with or without transfection reagents. The degree of protection matched the antiviral activity of the siRNA in cell culture, allowing an avenue for quick screening of an efficacious siRNA. When targeting both viruses in a joint infection, excess of one siRNA moderated the inhibitory effect of the other, suggesting competition for the RNAi machinery. Our results suggest that, if properly designed, low dosages of inhaled siRNA might offer a fast, potent and easily administrable antiviral regimen against respiratory viral diseases in humans.Keywords
This publication has 45 references indexed in Scilit:
- New drugs and treatment for respiratory syncytial virusReviews in Medical Virology, 2004
- Animal Pneumoviruses: Molecular Genetics and PathogenesisClinical Microbiology Reviews, 2004
- Enhanced Disease and Pulmonary Eosinophilia Associated with Formalin-Inactivated Respiratory Syncytial Virus Vaccination Are Linked to G Glycoprotein CX3C-CX3CR1 Interaction and Expression of Substance PJournal of Virology, 2003
- Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assayVirology, 2003
- The Complex Relationship between Respiratory Syncytial Virus and Allergy in Lung DiseaseViral Immunology, 2003
- A Role for Immune Complexes in Enhanced Respiratory Syncytial Virus DiseaseThe Journal of Experimental Medicine, 2002
- RSV entry inhibitors block F-protein mediated fusion with model membranesAntiviral Research, 2002
- Profilin Is Required for Optimal Actin-Dependent Transcription of Respiratory Syncytial Virus Genome RNAJournal of Virology, 2000
- Respiratory Syncytial Virus Genetic and Antigenic DiversityClinical Microbiology Reviews, 2000
- Role of Cellular Actin in the Gene Expression and Morphogenesis of Human Respiratory Syncytial VirusVirology, 1998